Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma

This is an open-label, multicenter, single arm efficacy and safety study in patients with
relapsed or refractory peripheral T-cell lymphoma, who have failed at least one prior
systemic therapy.

Approximately 120 patients will be enrolled. Patients will be treated with 1000 mg/m²
belinostat administered as a 30-minute IV infusion on days 1-5 of every 3-week cycle until
there is disease progression or unmanageable treatment-related toxicities.

The primary study endpoint is objective response rate (ORR) based on the IHP revision IWG
criteria. Safety will be evaluated during the study and for 30 days after the last
administration of study drug. Adverse events and laboratory studies will be graded according
to NCI-CTCAE v. 3.0.